Overview / Abstract: |
Educational Objectives 1. Identify patient-specific treatment goals in T2DM that reflect disease severity, comorbidities, therapeutic risks, and psychosocial status 2. Discuss the profiles, evidence for clinical benefits, and associated warnings for noninsulin antihyperglycemic medications 3. Intensify multidrug noninsulin regimens for various patient types to optimize glycemic control and improve other clinical parameters 4. Utilize motivational interviewing techniques to engage patients in their antidiabetes management plans, facilitate lifestyle changes, and improve treatment adherence Target Audience Statement of Need/Program Overview Physician Accreditation Statement Physician Credit Designation Global Contact Information Instructions to Receive Credit System Requirements MAC Fee Information & Refund/Cancellation Policy Disclosure of Conflicts of Interest The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: John E. Anderson, MD Consultant – Abbott Diabetes Care, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., sanofi-aventis U.S. LLC.Honoraria – Abbott Diabetes Care, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., sanofi-aventis U.S. LLC. Speakers Bureaus – Abbott Diabetes Care, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., sanofi-aventis U.S. LLC. Alan J. Garber, MD, PhD Consultant – Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S Julio Rosenstock, MD Consultant –AstraZeneca plc, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, sanofi-aventis U.S. LLC.,Takeda Pharmaceutical Company LimitedGrant/Research Support – AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Daiichi Sankyo Company, Limited, Eli Lilly and Company, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., F. Hoffmann-La Roche Ltd, sanofi-aventis U.S. LLC., Takeda Pharmaceutical Company LimitedHonoraria – AstraZeneca plc, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, sanofi-aventis U.S. LLC., Takeda Pharmaceutical Company Limited. The following planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Amanda Glazar, PhD Nothing to disclose Disclosure of Unlabeled Use The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer |
Expiration |
Jan 01, 2018 |
Discipline(s) |
Dietetics / Dietitian CE, Nurse Practitioner , Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1.0 |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
John E. Anderson, MD Alan J. Garber, MD, PhD, FACE Julio Rosenstock, MD |
Sponsors / Supporters / Grant Providers |
This activity is jointly provided by Global Education Group and Integritas Communications. |
Keywords / Search Terms |
Integritas Communications Integritas Communications, type 2 diabetes mellitus (T2DM), Free CE CME Free CE CME |